Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-armed, phase II clinical multicentre randomized, placebo-controlled (2:1), blinded with open-label extension trial (TEFIBEOS)
RecruitingCTIS2024-510884-51-00
Philipps-Universitaet MarburgProgressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia
Start: 2025-06-09Target: 39Updated: 2025-11-12